骨肉瘤
去细胞化
化学
紫杉醇
细胞外基质
体内
生物医学工程
体外
脚手架
透明质酸
药物输送
癌症研究
化疗
基质(化学分析)
组织工程
生物物理学
复合数
微透析
佐剂
基质金属蛋白酶
骨癌
纳米颗粒
控制释放
胃蛋白酶
药品
毒品携带者
作者
He Chen,Kaili Ye,C Zhang
标识
DOI:10.1080/1061186x.2026.2666805
摘要
A novel local chemotherapy delivery system was developed to improve the therapeutic efficacy of paclitaxel (PTX) for osteosarcoma while reducing systemic toxicity, low bioavailability, and tumour recurrence. PTX-loaded polylactic-co-glycolic acid nanoparticles (PLGA/PTX) were fabricated by an emulsification solvent evaporation method. Meanwhile, low-immunogenicity bone extracellular matrix (ECM) was prepared from porcine/bovine femurs through gradient decellularization combined with physical, chemical, and enzymatic treatments, followed by pepsin digestion to create a temperature-responsive injectable hydrogel. PLGA/PTX nanoparticles were incorporated into the bone ECM pre-gel to form a composite hydrogel system (H@PLGA/PTX). The processed bone ECM achieved over 97% decellularization while preserving collagen structure and biocompatibility. The composite hydrogel exhibited a porous three-dimensional network and released 62.5 ± 4.5% of PTX within 48 h under mildly acidic conditions (pH 6.5). In vitro assays showed superior anti-tumour effects against MG-63 osteosarcoma cells compared with free PTX. In vivo studies demonstrated significant tumour inhibition, stable body weight, and prolonged survival, associated with enhanced Caspase-3–mediated apoptosis. Overall, H@PLGA/PTX provides sustained local drug release with strong anti-tumour activity and low systemic toxicity, offering a promising strategy for adjuvant osteosarcoma chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI